TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31305338

Group type: EXPERIMENTAL
Intervention: Methadone 5 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methadone 10 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.4 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29084540

Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (AN)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 231
Study: 26104600

Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg canagliflozin
Number of subjects: 0
Study: 23871435

Group type: EXPERIMENTAL
Intervention: 10-month parenting program delivered to mothers, including group meetings and home visits focusing on hygiene, responsive feeding, play, communication, gentle discipline, and nutritious foods.
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: 10-month parenting program delivered to mothers.
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control group received standard government care.
Number of subjects: 463
Study: 21638329

Group type: COMPARATOR
Intervention: Ziprasidone (placebo-controlled trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ziprasidone (active comparator trials with risperidone and olanzapine)
Number of subjects: 0
Study: 19490477

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed milk formula (HF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cow's milk‐based formula (CMF)
Number of subjects: 80
Study: 16738349

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) group intervention, twice weekly for 8 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 91
Study: 15523313

Group type: EXPERIMENTAL
Intervention: High-grade residual stenosis
Number of subjects: 240

Group type: COMPARATOR
Intervention: Low-medium-grade lesion
Number of subjects: 240
Study: 11149032

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (10 million units, three times a week for 24 weeks)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b
Number of subjects: 71
Study: 9102064

Group type: EXPERIMENTAL
Intervention: Etidronate 400 mg once daily for 14 days followed by 76 days of 500 mg of elementary calcium once daily, repeated every 3 months.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Calcium 500 mg once daily.
Number of subjects: 80
Study: 8263386

Group type: EXPERIMENTAL
Intervention: Bismuth iodoform paraffin paste (BIPP) pack
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Telfa pack
Number of subjects: 95

Group type: COMPARATOR
Intervention: No pack
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Silastic nasal splint with BIPP
Number of subjects: 95

Group type: COMPARATOR
Intervention: Silastic nasal splint without BIPP
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BIPP pack
Number of subjects: 95
Study: 3896368

Group type: EXPERIMENTAL
Intervention: Short peri-operative antibiotic course
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no antibiotic course)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 192
Study: 31819863

Group type: EXPERIMENTAL
Intervention: Silicone gel treatment applied twice per day for two months on the surgical wound site.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (Vaseline) treatment applied twice per day for two months on the surgical wound site.
Number of subjects: 64
Study: 29128898

Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) added to doxorubicin/cyclophosphamide (AC)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) added to doxorubicin/cyclophosphamide (AC) in RS low subgroup
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) added to doxorubicin/cyclophosphamide (AC) in RS intermediate subgroup
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) added to doxorubicin/cyclophosphamide (AC) in RS high subgroup
Number of subjects: 1065
Study: 26703653

Group type: EXPERIMENTAL
Intervention: Color It Real Program (intervention)
Number of subjects: 192
Study: 24337734

Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 240
Study: 22946455

Group type: EXPERIMENTAL
Intervention: Heat stress condition (50°C, 40% relative humidity)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (20°C, 40% relative humidity)
Number of subjects: 16
Study: 19540451

Group type: EXPERIMENTAL
Intervention: White MTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium aluminate cement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Positive control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 40
Study: 17463218

Group type: EXPERIMENTAL
Intervention: Standard breakfast containing fat as 30% of calories
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-fat breakfast containing fat as 60% of calories
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fasting (overnight fast of 10 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All conditions (fed and fasted)
Number of subjects: 12
Study: 15889513

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture with strong stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication (Control group I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional acupuncture (Control group II)
Number of subjects: 0
Study: 12477446

Group type: EXPERIMENTAL
Intervention: Chemoradiation and surgery
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 10000
Study: 9501783

Group type: EXPERIMENTAL
Intervention: intra‐umbilical vein injection of saline solution plus oxytocin
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: intra‐umbilical vein injection of saline solution alone
Number of subjects: 291

Group type: COMPARATOR
Intervention: expectant management
Number of subjects: 291
Study: 7698575

Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice daily for 4 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 1671875

Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CDA) at doses of 3 to 10.7 mg/m2/d, given as a continuous 5-day infusion
Number of subjects: 31
Study: 6131178

Group type: EXPERIMENTAL
Intervention: Immediate breast reconstruction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (reconstruction offered 12 months later)
Number of subjects: 64
Study: 31699716

Group type: EXPERIMENTAL
Intervention: Tablet-based application used by community health agents (CHAs) during home visits to improve child-rearing practices and child health indicators.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablet-based application used by CHAs.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 28151802

Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 IU) - 1 dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 IU) - 2 doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 IU) - 3 doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (no doses of erythropoietin)
Number of subjects: 0
Study: 26637964

Group type: EXPERIMENTAL
Intervention: Synchronous, online, 15-week weight loss program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 80
Study: 25038914

Group type: EXPERIMENTAL
Intervention: Moviprep®
Number of subjects: 266

Group type: COMPARATOR
Intervention: Phosphoral®
Number of subjects: 266
Study: 23030579

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention including medication reconciliation, inpatient counseling, simple adherence aids, and telephone follow‐up
Number of subjects: 125
Study: 20520621

Group type: EXPERIMENTAL
Intervention: Sildenafil (on-demand for 12 weeks)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Saffron (30 mg twice daily for 12 weeks)
Number of subjects: 346
Study: 18939513

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 93

Group type: COMPARATOR
Intervention: No amnioinfusion (Control)
Number of subjects: 93
Study: 16396651

Group type: EXPERIMENTAL
Intervention: 0.1% timolol hydrogel
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.5% timolol aqueous solution
Number of subjects: 24
Study: 12562339

Group type: EXPERIMENTAL
Intervention: 1,450-nm diode laser (SmoothBeam; Candela Corp., Wayland, MA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (untreated symmetrical matched areas)
Number of subjects: 25
Study: 10190759

Group type: EXPERIMENTAL
Intervention: Sertraline tablet formulation made in China (test tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sertraline tablet formulation made in England (reference tablet)
Number of subjects: 12
Study: 8027273

Group type: EXPERIMENTAL
Intervention: Ovulation induction using a luteinizing hormone-releasing hormone agonist plus human menopausal gonadotrophin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous cycles
Number of subjects: 0
Study: 2574729

Group type: EXPERIMENTAL
Intervention: Dilevalol 100 mg bid for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg bid for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg bid for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilevalol once-a-day dosing (same total daily dose as prior 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilevalol (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilevalol (in 15 patients)
Number of subjects: 0
Study: 7342

Group type: EXPERIMENTAL
Intervention: beta‐adrenoceptor antagonists
Number of subjects: 25
Study: 31885153

Group type: EXPERIMENTAL
Intervention: Retinol-binding protein 4 (RBP4)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-8
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-18
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CXC chemokine ligand 10 (CXCL10)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: RBP4
Number of subjects: 73
Study: 31621256

Group type: EXPERIMENTAL
Intervention: Acupuncture at Jiaji (EX-B 2), once a day for 10 days, needles retained for 30 min.
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group received mosapride citrate (5 mg, 3 times a day), bifidobacterium triple viable capsules (420 mg, twice a day), omeprazole (40 mg, twice a day), and antibiotics.
Number of subjects: 118
Study: 28490941

Group type: EXPERIMENTAL
Intervention: Hypnosis combined with conventional behavior management techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (conventional behavior management techniques only)
Number of subjects: 0
Study: 25742762

Group type: EXPERIMENTAL
Intervention: Sildenafil (PDE-5 inhibitor)
Number of subjects: 208
Study: 23817699

Group type: EXPERIMENTAL
Intervention: salsalate, 3.5 g/d
Number of subjects: 286

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 286
Study: 20215537

Group type: EXPERIMENTAL
Intervention: Anastrozole plus gefitinib
Number of subjects: 93

Group type: COMPARATOR
Intervention: Anastrozole plus placebo
Number of subjects: 93
Study: 18294741

Group type: EXPERIMENTAL
Intervention: MF59™-adjuvanted vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine
Number of subjects: 0
Study: 16754711

Group type: EXPERIMENTAL
Intervention: Prasugrel (40 mg loading, 7.5 mg maintenance, n = 1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading, 10 mg maintenance, n = 4)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading, 15 mg maintenance, n = 2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading, 75 mg maintenance, n = 2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg daily, n = 2)
Number of subjects: 9
Study: 12789875

Group type: EXPERIMENTAL
Intervention: Fall-focused pharmaceutical intervention program (FFPIP)
Number of subjects: 200
Study: 10641431

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions (difficulty level not specified)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Meta-analysis of spectral analysis studies
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cross-study correlations
Number of subjects: 146
Study: 8981339

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg daily)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Estradiol (50 micrograms/24 h) transcutaneously
Number of subjects: 53

Group type: COMPARATOR
Intervention: No substitution
Number of subjects: 53
Study: 1607498

Group type: EXPERIMENTAL
Intervention: Plasma exchange therapy (PE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 26
Study: 3928313

Group type: EXPERIMENTAL
Intervention: Cefotaxim (Claforan)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 764
Study: 31441999

Group type: EXPERIMENTAL
Intervention: Sacha inchi oil
Number of subjects: 13

Group type: COMPARATOR
Intervention: Olive oil (benchmark)
Number of subjects: 13
Study: 29655627

Group type: EXPERIMENTAL
Intervention: PXVX0200 (derived from the CVD 103‐HgR strain)
Number of subjects: 0
Study: 27314013

Group type: EXPERIMENTAL
Intervention: Digital Virtual Template Group (DVTG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Hand-Free Group (HFG)
Number of subjects: 23
Study: 24875033

Group type: EXPERIMENTAL
Intervention: Bicruciate substituting knee system
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional posterior stabilized system
Number of subjects: 124
Study: 22732098

Group type: EXPERIMENTAL
Intervention: Individually prescribed cognitive behavior therapy text modules with online therapist guidance
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 57
Study: 20657090

Group type: EXPERIMENTAL
Intervention: Dentifrice
Number of subjects: 42

Group type: COMPARATOR
Intervention: No Dentifrice (Control)
Number of subjects: 42
Study: 18596312

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg IV every 6 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg IV every 6 hours
Number of subjects: 20
Study: 16018840

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 301

Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 301
Study: 12449696

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study: 10049657

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 43
Study: 8523926

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of desmopressin acetate (DDAVP) at a dosage of 0.3 micrograms/kg, 35 minutes prior to plasmapheresis.
Number of subjects: 15

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 15
Study: 1838424

Group type: EXPERIMENTAL
Intervention: ICI 192,605 (100 mg orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6957991

Group type: EXPERIMENTAL
Intervention: 100 mg Pirenzepine daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: 1000 mg Cimetidine daily
Number of subjects: 126
Study: 31322918

Group type: EXPERIMENTAL
Intervention: All-suture anchors
Number of subjects: 16

Group type: COMPARATOR
Intervention: Titanium suture anchors
Number of subjects: 16
Study: 29076259

Group type: EXPERIMENTAL
Intervention: Health halo condition (unfamiliar nutrient-poor food/drink ads with healthy messages)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Nutrient-poor food/drink ads with other messages
Number of subjects: 138

Group type: COMPARATOR
Intervention: Healthy food/drink ads
Number of subjects: 138
Study: 26869586

Group type: EXPERIMENTAL
Intervention: TC + BRx
Number of subjects: 21

Group type: COMPARATOR
Intervention: TC + water
Number of subjects: 21

Group type: COMPARATOR
Intervention: BRx
Number of subjects: 21

Group type: COMPARATOR
Intervention: water
Number of subjects: 21
Study: 24852584

Group type: EXPERIMENTAL
Intervention: Oral bottled water
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous normal saline (maximum 2 L over 2 hours)
Number of subjects: 48
Study: 21342170

Group type: EXPERIMENTAL
Intervention: 1% nadifloxacin cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study: 19696604

Group type: EXPERIMENTAL
Intervention: Home healthcare (three home visits with evidence-based nursing care)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care (pain control and management through the pain clinic)
Number of subjects: 42
Study: 17097761

Group type: EXPERIMENTAL
Intervention: Caralluma extract (1 g per day for 60 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15563389

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 319
Study: 11451781

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 47088

Group type: EXPERIMENTAL
Intervention: Scores of 10, 20, 30, 40, 50, and 60
Number of subjects: 47088

Group type: EXPERIMENTAL
Intervention: Risk prediction models
Number of subjects: 47088
Study: 9559735

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 303
Study: 8022537

Group type: EXPERIMENTAL
Intervention: Gabapentin as add-on therapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 3363025

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 64
Study: 29353388

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection with 5 ml of 1% lidocaine and 80 mg of methylprednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional anatomic landmark palpation guidance injection with 5 ml of 1% lidocaine and 80 mg of methylprednisolone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional anatomic landmark palpation guidance injection
Number of subjects: 40
Study: 26861113

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES) with paclitaxel
Number of subjects: 137

Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty plus Bail-out Bare Metal Stenting (PTA±BMS)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 137
Study: 25250712

Group type: EXPERIMENTAL
Intervention: Bilateral thalamic deep brain stimulation (DBS)
Number of subjects: 5
Study: 24354627

Group type: EXPERIMENTAL
Intervention: ASAQ
Number of subjects: 534

Group type: COMPARATOR
Intervention: AL
Number of subjects: 534

Group type: COMPARATOR
Intervention: DHAPQ
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 534
Study: 20722814

Group type: EXPERIMENTAL
Intervention: Parental educational intervention (bookmark, booklet on pain management, and pain scale)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (only received a pain scale)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Parental educational intervention
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study: 18081735

Group type: EXPERIMENTAL
Intervention: Health-related quality of life questionnaires (EORTC QLQ C-30 and QLQ OES18)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Health-related quality of life questionnaires (specific scales: physical functioning, fatigue, and reflux)
Number of subjects: 96
Study: 16959672

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CI therapy) for subacute therapy group (3 to 9 months after stroke)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CI therapy) for chronic therapy group (1 year after stroke)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of subacute and chronic therapy groups
Number of subjects: 32
Study: 14594455

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing lutein, vitamins A, C and E, zinc, and copper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10671945

Group type: EXPERIMENTAL
Intervention: IGF‐I 50 microg/kg subcutaneously thrice daily during a six day study period
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IGF‐I treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 8
Study: 9190048

Group type: EXPERIMENTAL
Intervention: Implicit memory test using picture fragments; explicit memory test with yes/no recognition.
Number of subjects: 0
Study: 1341893

Group type: EXPERIMENTAL
Intervention: Bretylium tosylate (5 mg/kg every 6 hours for 48-72 hours)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nitroglycerin (control group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bretylium tosylate
Number of subjects: 63
Study: 3897961

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) 20 mg/kg, two intravenous injections
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 181
Study: 30867079

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control [CON]) for 6 months
Number of subjects: 0
Study: 29411314

Group type: EXPERIMENTAL
Intervention: Telephone counseling exercise (TCE) intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Self-directed exercise (SDE) group
Number of subjects: 51
Study: 27349219

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 25277334

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 485